Please select the option that best describes you:
Topics:
Radiation Oncology • Gastrointestinal Cancers • Gastric Cancer • Medical Oncology • Colorectal Cancer • Liver and Pancreas Tumors • Hepatocellular Carcinoma • Pancreatic Cancer • Gastric/GEJ Cancer • ASCO 2023
What are your top takeaways from ASCO GI 2023?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
Answer from: Radiation Oncologist at Academic Institution
Top 3 radiation oncology studies:
Abstract 489- NRG/RTOG 1112 presented at ASTRO but only phase III study to establish the role of liver SBRT in HCC; will SBRT supplant radioembolization given the 3 negative phase III studies for radioembolization in contrast to this positive study for SBRT
Abstra...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
NALIRIFOX vs Gem/Abraxane in advanced pancreatic cancer: Minor improvement in mOS and unclear if similar results would have been seen with FOLFIRINOX vs Gem/Abraxane. Until future head-to-head trials of FOLFIRINOX vs Gem/Abraxane are reported (PASS-01 and PRECISION PROMISE), this trial likely make...
Answer from: Medical Oncologist at Academic Institution
SUNLIGHT study: This is a phase III global study for metastatic colorectal cancer patients who had previous 1-2 lines of chemotherapy to get randomized (1:1) to either TAS102 alone or TAS102 plus bevacizumab. The primary endpoint of the study is overall survival (OS). This study enrolled 492 patie...
Answer from: Medical Oncologist at Academic Institution
I think the GAP (gem cis abraxane) presentation by Dr. @Shroff was a good takeaway - more didn't equal more when it comes to efficacy but did add more toxicity. The question in my practice is whether there is still a role for this regimen in the subsets of patients who did better- gallbladder...
Answer from: Medical Oncologist at Academic Institution
SPOTLIGHT study (Shitara et al.) - For patients with unresectable/metastatic GEJ/gastric adenocarcinoma with positive CLDN18.2 expression, the addition of Zolbetuximab (mAb targeting CLDN18.2) to frontline FOLFOX chemotherapy improved PFS from 8.67 to 10.61 most (HR 0.751) and OS from 15.54 t...
Answer from: Medical Oncologist at Academic Institution
SUNLIGHT trial showing Lonsurf (TAS-102) plus bevacizumab provides a survival advantage in 3rd line colorectal cancer treatment.
Phase 1 trial of botensilimab/balstilimab (“bot/bal”) in MSS colorectal cancer – this is a subgroup that has been almost impossible to see any re...
Answer from: Medical Oncologist at Academic Institution
SPOTLIGHT – the benefits of adding zolbetuximab to mFOLFOX6 for claudin 18.2+ G/GEJ adenocarcinoma underscored the need to test for his biomarker as part of a fully informed approach to upper GI malignancy, including her2, PDL1, MMR, and FGFR2
MOUNTAINEER-03 – the accelerated FDA appr...
Answer from: Radiation Oncologist at Academic Institution
Canadian Cancer Trials Group HE.1: A phase III study of palliative radiotherapy for symptomatic hepatocellular carcinoma and liver metastases.
This multi-center, phase III trial randomized patients with painful hepatocellular carcinoma (HCC) or liver metastases (LM) 1:1 to BSC alone or with sin...